References
Scholz H. Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther 1997;10(Suppl. 3):869–872.
Opie LH. Should calcium antagonists be used after myocardial infarction? Ischemia selectivity versus vascular selectivity. Cardiovasc Drugs Ther 1992;6:19–24.
Heusch G. Ischemia-selectivity: A new concept of cardioprotection by calcium antagonists. Basic Res Cardiol 1994;89:2–5.
Schulz R, Post H, Jalowy A, et al. Unique cardioprotective action of the new calcium antagonist mibefradil. Circulation 1999;99:305–311.
Ross J, Jr. Mechanisms of regional ischemia and antianginal drug action during exercise. Prog Cardiovasc Dis 1989;31:455–466.
Roux S, Bühler M, Clozel J-P. Mechanism of the antiischemic effect of mibefradil, a selective T calcium channel blocker in dogs: Comparison with amlodipine. J Cardiovasc Pharmacol 1996;27:132–139.
Clozel J-P, Banken L, Osterrieder W. Effects of Ro 40–5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: Comparison with verapamil. J Cardiovasc Pharmacol 1989;14:713–721.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Behrends, M., Schulz, R. & Heusch, G. Effects of Verapamil and Mibefradil on Regional Blood Flow and Function in Normal and Ischemic Myocardium. Cardiovasc Drugs Ther 13, 275–276 (1999). https://doi.org/10.1023/A:1007760512698
Issue Date:
DOI: https://doi.org/10.1023/A:1007760512698